Acupuncture for nocturia in survivors of prostate cancer

JAMA Oncology

2025-05-29

(Press-News.org) About The Study: In this pilot trial, acupuncture produced greater reductions in nocturia (waking up 1 or more times to urinate) relative to usual care in survivors of prostate cancer. The nocturia reduction was comparable to other treatments, such as desmopressin, α-blockers, and antimuscarinic medications; however, acupuncture was associated with fewer adverse events. Nocturia affects more than half of survivors of prostate cancer.

Corresponding Author: To contact the corresponding author, Kevin T. Liou, MD, email liouk@mskcc.org.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaoncol.2025.1199)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.1199?guestAccessKey=76314b83-8573-4cfc-b733-28ac49d80ea1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052925

END

ELSE PRESS RELEASES FROM THIS DATE:

New study finds recovery is still possible for critically endangered Hawaiian honeycreeper with urgent intervention

2025-05-29

CONTACT: San Diego Zoo Wildlife Alliance Public Relations 619-685-3291 publicrelations@sdzwa.org sdzwa.org PHOTOS AND VIDEO: https://sandiegozoo.box.com/s/uzfr25f5xzcgxyj0tgww5ob6nvafuyng NEWS RELEASE New Study Finds Recovery Is Still Possible for Critically Endangered Hawaiian Honeycreeper With Urgent Intervention Latest Genomic Research Offers a Unique Lens for Understanding the Extinction Crisis in Hawai‘i SAN DIEGO (May 29, 2025) – A new scientific study, led by San Diego Zoo ...

All-in-one model reconstructs complex liver architecture

2025-05-29

To the point: New tissue-derived organoid model: A next-generation organoid model, composed of three liver cell types – adult hepatocytes, cholangiocytes, and liver mesenchymal cells – reconstructs the liver periportal region. Organoid functionality: The complex organoids, or assembloids, are functional, consistently draining bile from the bile canaliculi into the bile duct as in the real liver due to their accurate tissue architecture recapitulation. Liver disease modelling: This liver model reconstructs the liver periportal region architecture, is able to model aspects of cholestatic liver injury and biliary ...

Most Americans unaware of cancer risks associated with drinking alcohol

2025-05-29

Despite established connections, study finds almost 60% of U.S. adults are unaware or uncertain of the link between alcohol and cancer An estimated 75,000 cancer cases are associated with alcohol annually in the U.S. Researchers suggest implementing new Surgeon General recommendations could be an effective approach to reducing future cancer rates HOUSTON, MAY 29, 2025 ― Alcohol is a leading preventable cause of cancer, but public awareness of the connection remains strikingly low in the U.S., with ...

New insights into bladder cancer treatment could help improve immunotherapies

2025-05-29

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer. Now, a team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) and is expanding the understanding of how the treatment works — an understanding that could help improve the effectiveness of immunotherapies more broadly. BCG is a weakened strain of the bacterium Mycobacterium bovis, which is ...

HIV discovery could open door to long-sought cure

2025-05-29

University of Virginia School of Medicine scientists have uncovered a key reason why HIV remains so difficult to cure: Their research shows that small changes in the virus affect how quickly or slowly it replicates, and how easily or stubbornly it can reawaken from hiding. These insights bring researchers closer to finding ways to flush out the dormant virus and eliminate it for good. Thanks to remarkable progress in HIV treatment, the virus can often be suppressed to undetectable levels in the blood, eliminating most disease symptoms, and preventing transmission to others. But HIV never truly ...

The purrfect gene

2025-05-29

Kyoto, Japan -- Whether you are lucky enough to have a cat companion or must merely live this experience vicariously through cat videos, Felis catus is a familiar and comforting presence in our daily lives. Unlike most other feline species, cats exhibit sociality, can live in groups, and communicate both with other cats and humans, which is why they have been humans' trusted accomplices for millennia. Despite this intimacy, there is still much that we don't know about our feline friends. Numerous behavioral studies have been conducted on other mammal species, but relatively few on cats. In part to fill this gap, a team of researchers at ...

Researchers find promise in a new peptide drug to combat a deadly brain cancer

2025-05-29

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published in May in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that shows promise for therapeutic intervention. The group outlined the mechanism of action and effectiveness of the experimental drug known as JM2, revealing ...

Two WCM scientists receive inaugural Pershing Square Foundation Ovarian Cancer Challenge Grant

2025-05-29

(New York, May 29, 2025) – Dr. Juan R. Cubillos-Ruiz, the William J. Ledger, M.D. Distinguished Associate Professor of Infection and Immunology in Obstetrics and Gynecology, and Dr. David Lyden, the Stavros S. Niarchos Professor in Pediatric Cardiology, both from Weill Cornell Medicine, have been named inaugural recipients of the Pershing Square Foundation’s 2025 Ovarian Cancer Challenge Grant. The challenge grant provides $750,000 in funding over three years to support innovative research into ovarian cancer ...

Wyss Institute at Harvard University announces appointment of Natalie Artzi, Ph.D., to Associate Institute Director

2025-05-29

Wyss Institute at Harvard University Announces Appointment of Natalie Artzi, Ph.D., to Associate Institute Director Dr. Artzi will work closely with the Wyss Founding Director Don Ingber and the Wyss executive and senior leadership teams in shaping the strategic direction of the Institute MAY 29,2025 – (Boston, MA) – The Wyss Institute at Harvard University, its Board of Directors, and Executive Leadership are pleased to announce that Natalie Artzi, Ph.D. has been appointed to a newly created position as Associate Institute Director ...

Earlier measles vaccine could help curb global outbreak

2025-05-29

The global measles outbreak must trigger an urgent debate into whether a vaccine should be recommended earlier to better protect against the highly contagious disease during infancy, a new review states. The systematic review, led by Murdoch Children’s Research Institute (MCRI), found vaccinating children from as early as four months of age for measles warranted serious discussion given that only 30 per cent of babies in low- and middle-income countries were protected by maternal antibodies by four months of age. Concerningly, this is well below the World Health Organization’s (WHO) recommendation of a first measles dose between 9-12 months old. The ...

LAST 30 PRESS RELEASES:

Black youth, especially Black girls, use mental health services less than their White peers

Canada must protect youth from sports betting advertising

First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial

Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC